Denali Capital shareholders approve extension to Dec 2025; ~708K shares redeemed for ~$8.6M

Semnur Pharmaceuticals, Inc.

Shareholders voted to extend business combination deadline to December 11, 2025, via up to 8 monthly extensions.
Holders of ~708,098 Class A shares redeemed for ~$8.6M (~$12.17/share); only 43,739 Class A shares remain outstanding.
Company deposited $874.78 into trust for first extension to May 11, 2025, funded by Scilex convertible note (up to $180K).
Scilex note bears no interest, convertible at $10/share; remaining $58,670.30 available for future extensions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.